ELI LILLY & CO (LLY)       340.5  -1.6 (-0.47%)

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. The company maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000.0

CEO: David A. Ricks

Employees: 35000

Website: https://www.lilly.com/